Prediction of Major Adverse Cardiovascular Events in Patients With Hypertrophic Cardiomyopathy Using Proteomics Profiling.
Yuichi J ShimadaYoshihiko RaitaLusha W LiangMatthew John MaurerKohei HasegawaMichael A FiferMuredach P ReillyPublished in: Circulation. Genomic and precision medicine (2022)
This study serves as the first to demonstrate the ability of proteomics profiling to predict MACE in hypertrophic cardiomyopathy, exhibiting both novel (eg, Ras-MAPK) and known (eg, TGF-β) pathways differentially regulated in patients who subsequently experience MACE.